Articles by Tom Hargreaves
ASX: RAD's Busy 2026: Inside Radiopharm's Pipeline of Upcoming Clinical Data Readouts
Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX) has entered 2026 as one of the more closely watched names on the ASX's...
ASX dividend ETFs in 2026: what's out there, how they differ, and what actually matters
There are more ASX-listed dividend ETFs now than at any point in the market's history. Some launched decades ago. Some l...
RBA Hits the Pause Button: Cash Rate Stays at 4.35% After Three Straight Hikes
Australia's central bank has pressed pause on its rate-hiking cycle — but homeowners shouldn't celebrate just yet.The Re...
How Are Higher Interest Rates Hitting Australian REITs in 2026?
There have been difficult times for A-REITs and they aren’t over just yet, as the RBA raised interest rates three times...
Which ASX Healthcare Stocks Have Clinical Trials Running in June 2026?
The coming June 2026 will likely prove to be one of the most eventful months ever for ASX healthcare stocks. In fact, th...